{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:59:39Z","timestamp":1772114379716,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02531","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T04:32:41Z","timestamp":1541133161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants"],"prefix":"10.3389","volume":"9","author":[{"given":"Mar\u00eda B.","family":"Pampena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holliday C.","family":"Cartar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo Rub\u00e9n","family":"Cueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrella M.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula A.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda M.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3389\/fimmu.2017.00625","article-title":"Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus Bacillus Calmette-Guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose Interferon alpha 2B in Stages IIB, IIC, and III cutaneous melanoma patients: a single institution, randomized study","volume":"8","author":"Mordoh","year":"2017","journal-title":"Front Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"Diagnosis and treatment of melanoma","volume":"63","author":"Garbe","year":"2016","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.smim.2015.11.002","article-title":"Cancer immunotherapy targeting neoantigens","volume":"28","author":"Lu","year":"2016","journal-title":"Semin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"2045","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1016\/j.vaccine.2016.08.048","article-title":"Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization","volume":"34","author":"Penaloza-MacMaster","year":"2016","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-5-19","article-title":"Monocyte-derived dendritic cells loaded with a mixture of apoptotic\/ necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+T lymphocytes","volume":"5","author":"von Euw","year":"2007","journal-title":"J Transl Med."},{"key":"B11","unstructured":"Di RienzoJA\n            CasanovesF\n            BalzariniMG\n            GonzalezL\n            TabladaM\n          RC InfoStat Versi\u00f3n 20172017"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-87458-6","volume-title":"Mixed Effects Models and Extensions in Ecology with R","author":"Zuur","year":"2009"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1114","DOI":"10.7717\/peerj.1114","article-title":"A comparison of observation-level random effect and Beta-Binomial models for modelling overdispersion in Binomial data in ecology & evolution","volume":"3","author":"Harrison","year":"2015","journal-title":"PeerJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1198\/10857110260141193","article-title":"A multiple-comparisons method based on the distribution of the root node distance of a binary tree","volume":"7","author":"Di Rienzo","year":"2002","journal-title":"J Agric Biol Environ Stat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fimmu.2018.00955","article-title":"Changes in the TCR\u03b2 repertoire and tumor immune signature from a cutaneous melanoma patient immunized with the CSF-470 vaccine: a case report","volume":"9","author":"Aris","year":"2018","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","article-title":"Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters","volume":"70","author":"Del Giudice","year":"2018","journal-title":"Brain Behav Immun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF01988730","article-title":"Stimulation of CRP secretion in HepG2 cells: Cooperative effect of dexamethasone and interleukin 6","volume":"34","author":"Depraetere","year":"1991","journal-title":"Agents Actions"},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1399-302X.1998.tb00729.x","article-title":"Interleukin-6 production by human monocytes treated with granulocyte-macrophage colony-stimulating factor in the presence of lipopolysaccharide of oral microorganisms","volume":"13","author":"Baqui","year":"1998","journal-title":"Oral Microbiol Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/0008-5472.CAN-10-2693","article-title":"Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases","volume":"71","author":"Corbi\u00e8re","year":"2011","journal-title":"Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S1471-4906(02)00029-7","article-title":"Determinant spreading and tumor responses after peptide-based cancer immunotherapy","volume":"24","author":"Ribas","year":"2003","journal-title":"Trends Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3389\/fimmu.2017.01342","article-title":"Early events of the reaction elicited by CSF-470 melanoma vaccine plus adjuvants: an in vitro analysis of immune recruitment and cytokine release","volume":"8","author":"Pampena","year":"2017","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/CVI.00162-15","article-title":"Mycobacterium bovis BCG vaccination induces divergent proinflammatory or regulatory T cell responses in adults","volume":"22","author":"Boer","year":"2015","journal-title":"Clin Vaccine Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0014-5793(89)80476-4","article-title":"Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes","volume":"242","author":"Castell","year":"1989","journal-title":"FEBS Lett."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1172\/JCI44952DS1","article-title":"IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells","volume":"121","author":"Fisher","year":"2011","journal-title":"J Clin Investig."},{"key":"B26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1586\/1744666x.4.3.379","article-title":"C-reactive protein at the interface between innate immunity and inflammation","volume":"4","author":"Peisajovich","year":"2008","journal-title":"Expert Rev Clin Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2011.37","article-title":"C-reactive protein in rheumatology: biology and genetics","volume":"7","author":"Rhodes","year":"2011","journal-title":"Nat Rev Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3389\/fimmu.2018.00675","article-title":"A conformational change in C-reactive protein enhances leukocyte recruitment and reactive oxygen species generation in ischemia\/reperfusion injury","volume":"9","author":"Thiele","year":"2018","journal-title":"Front Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc3162","article-title":"Choline metabolism in malignant transformation","volume":"11","author":"Glunde","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphar.2017.00012","article-title":"Targeting membrane lipid a potential cancer cure?","volume":"8","author":"Tan","year":"2017","journal-title":"Front Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"52552","DOI":"10.1074\/jbc.M409054200","article-title":"Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications","volume":"279","author":"Suresh","year":"2004","journal-title":"J Biol Chem."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T04:33:10Z","timestamp":1541133190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2018.02531"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02531","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]},"article-number":"2531"}}